BIOLASE, INC Form 10-Q August 09, 2013

#### **UNITED STATES**

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 10-Q

(Mark One)	
xQUARTERLY REPOR 1934	T PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the quarterly period ended June 30, 2013
	OR
"TRANSITION REPOR'	Γ PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
17J4	For the transition period from to
	Commission File Number 000-19627

BIOLASE, INC.

(Exact name of registrant as specified in its charter)

Delaware

87-0442441

#### Edgar Filing: BIOLASE, INC - Form 10-Q

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

4 Cromwell

Irvine, California 92618

(Address of principal executive offices, including zip code)

(949) 361-1200

(Registrant s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definition of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer " Accelerated filer x

Non-accelerated filer  $\,^{''}$  (Do not check if a smaller reporting company) Smaller reporting company  $\,^{''}$  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes  $\,^{''}$  No  $\,^{''}$ 

The number of shares of the issuer s common stock, \$0.001 par value per share, outstanding, as of August 2, 2013, was 33,960,650 shares.

# Edgar Filing: BIOLASE, INC - Form 10-Q BIOLASE, INC.

# INDEX

		Page
PART I.	FINANCIAL INFORMATION	
Item 1.	Financial Statements (Unaudited):	
	Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012	3
	Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2013 and June 30, 2012	4
	Consolidated Statements of Cash Flows for the six months ended June 30, 2013 and June 30, 2012	5
	Notes to Consolidated Financial Statements	6
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	28
Item 4.	Controls and Procedures	28
PART II	OTHER INFORMATION	
Item 1.	Legal Proceedings	28
Item 1A.	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3.	<u>Defaults Upon Senior Securities</u>	28
Item 4.	Mine Safety Disclosures	28
Item 5.	Other Information	28
Item 6.	<u>Exhibits</u>	29
Signatures		31

### PART I. FINANCIAL INFORMATION

## ITEM 1.FINANCIAL STATEMENTS

## BIOLASE, INC.

## CONSOLIDATED BALANCE SHEETS (Unaudited)

(in thousands, except per share data)

	June 30, 2013		December 31, 2012	
ASSETS				
Current assets:				
Cash and cash equivalents	\$	2,101	\$	2,543
Accounts receivable, less allowance of \$380 in 2013 and \$304 in 2012		11,477		11,680
Inventory, net		12,559		11,142
Prepaid expenses and other current assets		1,341		1,552
Total current assets		27,478		26,917
Property, plant, and equipment, net		1,581		1,509
Intangible assets, net		217		300
Goodwill		2,926		2,926
Deferred tax asset		16		16
Other assets		245		305
Total assets	\$	32,463	\$	31,973
LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT)				
Current liabilities:				
Lines of credit	\$	5,992	\$	1,637
Accounts payable		9,299		7,663
Accrued liabilities		5,084		6,267
Customer deposits		174		582
Deferred revenue, current portion		3,123		3,226
Total current liabilities		23,672		19,375
Deferred tax liabilities		591		663
Other liabilities, long-term		34		141
Total liabilities		24,297		20,179
Commitments and contingencies (Notes 8, 9, and 13)				
Stockholders equity (deficit):				
Preferred stock, par value \$0.001, 1,000 shares authorized, no shares issued and outstanding				
		34		34

## Edgar Filing: BIOLASE, INC - Form 10-Q

Common stock, par value \$0.001, 50,000 shares authorized; 33,958 and 33,248 shares issued in 2013 and 2012, respectively; and 31,995 and 31,284 shares outstanding in 2013 and 2012, respectively

Additional paid-in capital	142,383	140,747
Accumulated other comprehensive loss	(385)	(320)
Accumulated deficit	(117,467)	(112,268)
	24,565	28,193
Treasury stock (cost of 1,964 shares repurchased)	(16,399)	(16,399)
Total stockholders equity	8,166	11,794
Total liabilities and stockholders equity	\$ 32,463 \$	31,973

See accompanying notes to consolidated financial statements.

# Edgar Filing: BIOLASE, INC - Form 10-Q BIOLASE, INC.

# CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)

(in thousands, except per share data)

	Three Months Ended		Six Mont	hs Ended
	June 30,		June 30,	
	2013	2012	2013	2012
Products and services revenue	\$ 14,208	\$ 12,125	\$ 28,697	\$ 24,437
License fees and royalty revenue	39	50	147	58
Net revenue	14,247	12,175	28,844	24,495
Cost of revenue	8,686	6,675	17,489	13,188
Gross profit	5,561	5,500	11,355	11,307
Operating expenses:				
Sales and marketing	4,138	3,720	9,390	